

AMBULATORY INFUSION AND IN HOME ORDERS/SPECIALTY ORDERS

Referral Status:	MRN:
<input type="checkbox"/> New referral	<input type="checkbox"/> Order change
<input type="checkbox"/> Order Renewal	
Patient preferred clinic:	

Rev 3.14.25

Stelara® (ustekinumab) Standard Plan of Treatment for Gastroenterology

PATIENT DEMOGRAPHICS:

Date of Referral:	Patient's Phone:				
Patient Name:	Address:				
Date of Birth:	City, State, Zip:				
Height in inches:	Weight: LB or KG	Gender:	Allergies:	See list	NKDA

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

K50.0 - Crohn's disease (small intestine)	K51.2 - Ulcerative (chronic) proctitis
K50.1 - Crohn's disease (large intestine)	K51.3 - Ulcerative (chronic) rectosigmoiditis
K50.8 - Crohn's disease (small & large intestine)	K51.5 - Left sided colitis
K50.9 - Crohn's disease, unspecified	K51.8 - Other ulcerative colitis
K51.0 - Ulcerative (chronic) pancolitis	K51.9 - Ulcerative colitis, unspecified
- Other:	

REQUESTED DOCUMENTATION:

1 Insurance information	IF NO:	IF YES:
2 Most recent History & Physical	PLEASE STATE	LAST INFUSION DATE:
3 Full medication list	REQUIRED WASHOUT	NEXT INFUSION DATE:
4 Tried and failed therapies	FROM PREVIOUS	IF ORDER CHANGE:
5 REQUIRED: TB screening for new start patients	THERAPY:	Continue current order until insurance approved

AMBULATORY INFUSION MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive ustekinumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, and/or surgery

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

FDA labeling does not suggest premedication.

IV	Diphenhydramine	25mg	50mg		PO	Acetaminophen	325mg	500mg	650mg	1000mg
	Methylprednisolone	40mg	125mg	Other:		Famotidine	20mg	40mg		
	Famotidine	20mg	40 mg			Diphenhydramine	25mg	50mg		
	Other:					Fexofenadine	60mg	180mg		
					Cetirizine	10mg				
					Loratadine	10mg				
					Other:					

MEDICATION/DOSE/FREQUENCY:

Induction: Stelara® (ustekinumab) single IV dose per 250ml NS IV to infuse over at least 1 hour.

Body weight of patient	Dose
less than 55 kg	260 mg
55-85 kg	390 mg
greater than 85kg	520 mg

SPECIAL/LAB ORDERS:

IN HOME/SPECIALTY PHARMACY ORDERS:

Maintenance: Stelara® (ustekinumab) 90 mg subcutaneously 8 weeks after initial IV and every 8 weeks thereafter

Administer as subcutaneous injection to upper arm, thigh, or abdomen.

Some commercial insurance plans require maintenance doses to be provided by the plan's specialty pharmacy. Providers will be notified if Palmetto Infusion cannot dispense the maintenance doses due to plan restrictions or patient preference.



Refills x 12 months unless noted otherwise here:

LINE USE/CARE ORDERS:

- Start PIV/Access CVC
- Flush device per facility standard flushing procedure
- Provide nursing care per Palmetto Infusion Nursing Procedures and post procedure observation if indicated
- In Home Supply orders: All supplies for drug administration and ADR kit to be provided for in home use.

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders which can be found on the website. Home Standing orders including Anaphylaxis Kit dispense as written and administer for mild and severe reactions are provided.

PRESCRIBER INFORMATION:

PROVIDER NAME:	PHONE:
ADDRESS:	FAX:
CITY, STATE, ZIP:	NPI:

PRESCRIBER SIGNATURE: (No stamp signatures)

DATE:

_____	_____
Dispense as written/Brand medically necessary	Substitution permitted



IN-HOME INFUSION PHYSICIAN STANDING ORDERS

(CHECK ALL APPLICABLE ORDERS)

Prescriber Office:	Phone:
--------------------	--------

Patient Name:	DOB:
---------------	------

Address:

City, State:	Phone:	Zip:
--------------	--------	------

PRESCRIPTION

By signing below, I authorize the administration of flush medications and their associated instructions to our patients. This authorization applies as relevant to the type of access device being utilized. The validity of this order extends for one year from the date of signing.

SKILLED NURSING

A skilled nurse is authorized to assess, administer, and/or provide self-administration education as appropriate. The nurse will offer ongoing support as required. Additionally, all vascular access and ancillary orders mentioned within may be refilled as directed for a duration of one year unless discontinued prior.

VASCULAR ACCESS & ANCILLARY ORDERS

- | | |
|---|--|
| <input type="checkbox"/> <u>Peripheral:</u> | <input type="checkbox"/> Insertion of 22 or 24 gauge peripheral IV as required for ordered infusion therapy.
<input type="checkbox"/> 0.9% sodium chloride 5 ml pre- and post-infusion.
<input type="checkbox"/> 0.9% sodium chloride 10 mL pre- and post-infusion.
<input type="checkbox"/> Other: _____ |
|---|--|

- | | |
|---|--|
| <input type="checkbox"/> <u>Peripheral-Midline, PICC and Central Tunneled and Non-Tunneled:</u> | <input type="checkbox"/> Access peripheral-midline, PICC, or central tunneled catheter as required.
<input type="checkbox"/> 0.9% sodium chloride 5ml pre- and post-infusion. (5 mL pre-lab draw).
<input type="checkbox"/> 0.9% sodium chloride 10mL pre- and post-infusion. (10 mL pre-lab draw).
<input type="checkbox"/> Heparin (10 unit/mL) 5 mL post-use for flush/locking procedure
For maintenance flushing/locking:
<input type="checkbox"/> 10 mL of 0.9% sodium chloride followed by 5 ml Heparin (100 unit/mL)
<input type="checkbox"/> Other: _____ |
|---|--|

- | | |
|---|--|
| <input type="checkbox"/> <u>Implanted Port:</u> | <input type="checkbox"/> Access the implanted port as required.
<input type="checkbox"/> 0.9% sodium chloride 5ml pre- and post-infusion. (5 mL pre-lab draw).
<input type="checkbox"/> 0.9% sodium chloride 10mL pre- and post-infusion. (10 mL pre-lab draw).
<input type="checkbox"/> Heparin (10 unit/mL) 5 mL post-use for flush/locking procedure
For maintenance flushing/locking:
<input type="checkbox"/> 10 mL of 0.9% sodium chloride followed by 5 ml Heparin (100 unit/mL)
<input type="checkbox"/> Other: _____ |
|---|--|

CATHETER OCCLUSION ORDERS

Cathflo Activase- Instill into the occluded catheter. Let dwell for 30 minutes before attempting to aspirate. Dwell time not to exceed 120 minutes.

- 1 mg (midlines or patients <30 kg)
 2 mg
 May repeat x 1 dose.

ANAPHYLAXIS ORDERS

MILD REACTION – Pruritis or rash, dizziness without blood pressure change, arthralgia, headache, nausea

- Stop Infusion and connect 5-10 ml syringe and draw back to a blood return to remove the existing drug in the line and discard. Flush line with 10 ml of 0.9% sodium chloride.
- Diphenhydramine IV:**
Dose:
 10 to 30 kg (22-66lbs) or (2-12 years old), 0.5ml (25mg) IV
 >30 kg (>66lbs) or over the age of 12 years old, 0.5 ml (25mg) IV
 >30 kg (>66lbs) or over the age of 12 years old, 1ml (50mg) IV
- May repeat x **1 Dose**. (Maximum Adult Daily Dose 300mg/day)
Monitor vital signs at 15-minute intervals. If patient is back to baseline after 30 minutes, then restart the infusion. If patient is not back at baseline and symptoms persist, continue to monitor, and reassess for 15 additional minutes and to include vitals with each 15-minute interval. When patient is back to baseline restart infusion as tolerated. If mild symptoms persist, call primary ordering physician for guidance to continue or discontinue therapy.

SEVERE REACTION/ANAPHYLAXIS- Urticaria, hypotension, chest pain, shortness of breath, stridor, wheezing, vomiting, severe abdominal or back pain.

- Stop Infusion and connect 5-10 ml syringe and draw back to a blood return to remove existing drug in the line and discard. Flush line with 10ml of 0.9% sodium chloride. Call EMS 911.
- Epinephrine IM Injection:** (Do Not Delay Epinephrine in favor of other drugs/adjunctive therapies.)
 Epinephrine IM Injection: **0.15ml/ 0.15mg, 5 to 30 kg (Children, 33 to 66 lbs.)** (Preferably thigh)
 Epinephrine IM Injection: **0.3 ml/0.3mg, >30 kg (patients weighing > 66 pounds)**
 If there is no response or an inadequate response, a second Epinephrine dose may be administered at 5 to 15 minutes after initial injection. Intramuscular injection is given into the mid-outer thigh.

Prescriber Signature:	Date:
-----------------------	-------

Authorizing Prescriber Name:	Phone:	Fax:
------------------------------	--------	------

Address:	NPI:
----------	------

City, State, Zip:	Office Contact:
-------------------	-----------------



Checklist for referrals to Palmetto Infusion: Fax referral to 1.800.521.9640

- Patient demographics - address, phone number, SS#, etc.**
- Insurance information - copy of the card(s) if possible**
- Plan of Treatment/Orders**
- Most recent physician office notes to include tried and failed therapies - all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs.**
- Any lab results or other diagnostic procedures to support the diagnosis.**

Palmetto Infusion will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility.

Our office will notify you if any further information is required.

We will review financial responsibility with patient and refer them to any available co-pay assistance as required. Palmetto Infusion Call Center 800.809.1265. Thank you for your referral.

www.PalmettoInfusion.com